Active Ingredient History

  • Now
Tirapazamine (SR-[[4233]]) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective. As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types.   Wikipedia

  • SMILES: Nc1n[n+]([O-])c2ccccc2[n+]1[O-]
  • Mol. Mass: 178.15
  • ALogP: -0.92
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No
1,2,4-benzotriazin-3-amine, 1,4-dioxide | 3-amino-1,2,4-benzothiadi- azine 1,1-dioxide | 3-amino-1,2,4-benzotriazine 1,4-dioxide | 3-amino-1,2,4-benzotriazine-1,4-dioxide | nsc 130181 | sr 4233 | sr-4233 | tirapazamine | tirazone | win 59075 | win-59075


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue